Scholarlink

Background <p>Portal hypertension is a major complication in patients with liver cirrhosis, leading to severe outcomes such as variceal bleeding and ascites. Transjugular intrahepatic portosystemic shunt (TIPS) has emerged as an effective interventional treatment of recurrent ascites and variceal bleeding. However, up to 30% of patients with recurrent ascites show TIPS refractory ascites, and prior data have shown that the frequency of paracenteses before TIPS implantation predicts ascites clearance indicating that TIPS implantation may be too late in some patients. Especially, patients with grade 2 ascites and a MELD score ≥ 15, or grade 3 ascites irrespective of MELD score at first decompensation with ascites face a high risk of further decompensation and mortality. Therefore, these patients may benefit from early TIPS implantation in order to improve post-TIPS mortality. We hypothesise that early TIPS implantation in these selected patients at the time of the first decompensation may improve transplantation-free survival compared to standard medical treatment (SMT).</p> Methods <p>The eTIPS study is a prospective, randomised, open, multicenter interventional, superiority trial. Patients will be randomised 1:1 in the intervention group with TIPS implantation and in the SMT group. The primary endpoint is transplantation-free survival. Secondary endpoints include the time to ascites with need for paracentesis and quality of life assessed six and 12&#xa0;months after randomisation.</p> Discussion <p>Expanding the concept of early TIPS implantation to ascites management may offer significant survival benefits and may significantly change the treatment algorithm of patients with ascites.</p> Trial registration <p>German Registry for Clinical Studies DRKS00034545. Registered on 20/02/2025.</p> <p>Clinical trials NCT06576934. Registered on 04/12/2024.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early implantation of a transjugular intrahepatic portosystemic shunt (TIPS) in patients with liver cirrhosis and ascites (eTIPS): a multicentre, randomised controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月2日

查看全文
  • Dominik Bettinger,
  • Marco Janoschke,
  • Carolin Jenkner,
  • Margit Kaufmann,
  • Julia van Gessel,
  • Hans-Heinrich Otter,
  • Michael Schultheiss,
  • Robert Thimme,
  • Lukas Sturm,
  • Marlene Reincke,
  • Michael Praktiknjo,
  • Jonel Trebicka,
  • Frank Erhard Uschner,
  • Markus Kimmann,
  • Michael Koehler,
  • Christian Labenz,
  • Eva Maria Scheicher,
  • Michael B. Pitton,
  • Johannes Chang,
  • Christian Jansen,
  • Carsten Meyer,
  • Benjamin Maasoumy,
  • Lisa Sandmann,
  • Bernhard Meyer,
  • Matti Joonas Peperhove,
  • Jens Marquardt,
  • Sven Danneberg,
  • Roman Kloeckner,
  • Alexander Zipprich,
  • Cristina Ripoll,
  • Rene Aschenbach,
  • Thomas Berg,
  • Jonas Schumacher,
  • Holger Goessmann,
  • Christian M. Lange,
  • Christiana Graf,
  • Moritz Wildgruber,
  • Tony Bruns,
  • Theresa Wirtz,
  • Philipp Bruners,
  • Anselm Kunstein,
  • Johannes Bode,
  • Peter Minko

摘要

Background

Portal hypertension is a major complication in patients with liver cirrhosis, leading to severe outcomes such as variceal bleeding and ascites. Transjugular intrahepatic portosystemic shunt (TIPS) has emerged as an effective interventional treatment of recurrent ascites and variceal bleeding. However, up to 30% of patients with recurrent ascites show TIPS refractory ascites, and prior data have shown that the frequency of paracenteses before TIPS implantation predicts ascites clearance indicating that TIPS implantation may be too late in some patients. Especially, patients with grade 2 ascites and a MELD score ≥ 15, or grade 3 ascites irrespective of MELD score at first decompensation with ascites face a high risk of further decompensation and mortality. Therefore, these patients may benefit from early TIPS implantation in order to improve post-TIPS mortality. We hypothesise that early TIPS implantation in these selected patients at the time of the first decompensation may improve transplantation-free survival compared to standard medical treatment (SMT).

Methods

The eTIPS study is a prospective, randomised, open, multicenter interventional, superiority trial. Patients will be randomised 1:1 in the intervention group with TIPS implantation and in the SMT group. The primary endpoint is transplantation-free survival. Secondary endpoints include the time to ascites with need for paracentesis and quality of life assessed six and 12 months after randomisation.

Discussion

Expanding the concept of early TIPS implantation to ascites management may offer significant survival benefits and may significantly change the treatment algorithm of patients with ascites.

Trial registration

German Registry for Clinical Studies DRKS00034545. Registered on 20/02/2025.

Clinical trials NCT06576934. Registered on 04/12/2024.